XORTX Announces Presentation at the Rare and Genetic Disease Summit
December 12 2024 - 9:17AM
XORTX Therapeutics Inc. ("
XORTX" or the
“
Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt:
ANU), a late-stage clinical pharmaceutical company focused on
developing innovative therapies to treat progressive kidney
disease, is pleased to announce a presentation by Dr. Allen
Davidoff at the Rare and Genetic Kidney Disease Summit, in Boston,
Massachusetts at 10:30 am ET, Thursday December 12, 2024. The
presentation entitled “Autosomal Dominant Polycystic Kidney Disease
- Genetic and Environmental Factors → Evidence for Aberrant Purine
Metabolism as a Second Hit Determining Disease Progression.”
The presentation highlights XORTX recent
pioneering discoveries in the field of Autosomal Dominant
Polycystic Kidney Disease (“ADPKD”), and recent peer-reviewed,
independent, published research reports identifying genetic factors
that influence over-expression of xanthine oxidase (“XO”) and play
a role in several diseases, including kidney disease. These
ground-breaking findings suggest that genetic factors that
influence aberrant purine metabolism may influence the rate of
progression of ADPKD.
Dr. Allen Davidoff, CEO of XORTX, stated, “The
recent identification of genetic factors that increase the
expression of XO, and/or contribute to chronic hyperuricemia
support the concept of a “second hit” – a factor or factors that
accelerate the rate of disease progression when present. These new
discoveries are an important first step in our understanding of why
ADPKD progression may vary substantially even amongst family
members. These discoveries highlight an opportunity to develop a
personalized therapeutic approach for individuals whose unique
genetic factors predisposed them to ADPKD, and the need for XO
inhibition to treat those individuals at risk. We believe that
XORTX’s expertise in developing XO inhibitors, protected by a
patent portfolio that anticipated this opportunity, combined with
our therapeutic platform is ideally positioned to deliver targeted
therapeutics to individuals. Our planned clinical trial in patients
with ADPKD will provide an opportunity to further understand the
role of these newly identified genetic factors in individuals with
progressive kidney disease.”
About Xanthine Oxidase
Evidence for over-expression of XO in human PKD
has not been reported to date, although work by Wang et al.
suggests linkage of genetic factors to PKD1. Recently, new emerging
discoveries link genetic factors to specific populations and show
that higher XO expression is associated with a variety of
conditions including hyperuricemia2, sepsis, organ failure and
sepsis associated acute respiratory distress syndrome (ARDS)3,4,
kidney dysfunction3,4, diabetes5, polycystic kidney disease1,5 and
kidney failure6,7. From a mechanistic standpoint, these studies
advocate for a precision-medicine approach in which genetic risk
variants would guide treatment decisions1.
References:
- Korsmo HW, Emerging roles of
xanthine oxidoreductase in chronic kidney disease, Antioxidants,
June 2024
- Major TJ, et all, Evaluation of the
diet wide contribution to serum urate levels: Met-analysis of
population-based cohorts, BMJ, 363, k3952, 2018
- Gao, Li et al., Xanthine
oxidoreductase gene polymorphism are associated with high risk of
sepsis and organ failure, Respir. Res, 24, 177_2023
- Liu H, et al., Genetic variants in
XDH are associated with prognosis off gastric cancer in a Chines
population, 663, 196, 2013
- Wang et al., Genetic susceptibility
to diabetic kidney disease is linked to promoter variants
of XOR. “The authors identified an expression quantitative
trait loci (QTL) in the cis-acting regulatory region of the
xanthine dehydrogenase, or xanthine oxidoreductase (XO), a binding
site for C/EBPβ, to be associated with diabetes-induced podocyte
loss in diabetic kidney disease in male mice. They concluded
that certain types of alleles of a gene that controls the
expression of xanthine oxidase can be over expressed in CKD,
diabetic kidney disease and polycystic kidney disease.
- Kudo M et al., Functional
Characterization of Genetic Polymorphisms Identified In the
Promotor Region of the Xanthine Oxidase Gene, Drug Metab.
Pharmacokinet., 25, 599, 2010
- Boban M, et al., Circulating purine
compound, uric acid, and xanthine oxidase/dehydrogenate
relationship in essential hypertension and end stage renal
disease., Ren. Fail., 36, 613, 2014
About XORTX
Therapeutics Inc.
XORTX is a
pharmaceutical company with two clinically advanced products in
development: 1) our lead, XRx-008 program for ADPKD; and 2) our
secondary program in XRx-101 for acute kidney and other acute organ
injury associated with Coronavirus / COVID-19 infection. In
addition, XRx-225 is a pre-clinical stage program for Type 2
Diabetic Nephropathy. XORTX is working to advance its clinical
development stage products that target aberrant purine metabolism
and xanthine oxidase to decrease or inhibit production of uric
acid. At XORTX, we are dedicated to developing medications to
improve the quality of life and health of kidney disease patients.
Additional information on XORTX is available at www.xortx.com.
For more information,
please contact:
Allen Davidoff, CEOadavidoff@xortx.com or +1 403 455 7727 |
Nick Rigopulos, Director of
Communicationsnick@alpineequityadv.com or +1 617 901 0785 |
|
|
Neither the TSX
Venture Exchange nor Nasdaq has approved or disapproved the
contents of this news release. No stock exchange, securities
commission or other regulatory authority has approved or
disapproved the information contained herein.
Forward
Looking Statements
This press release
contains express or implied forward-looking statements pursuant to
applicable securities laws. These forward-looking statements
include, but are not limited to, the Company's beliefs, plans,
goals, objectives, expectations, assumptions, estimates,
intentions, future performance, other statements that are not
historical facts and statements identified by words such as
"expects", "anticipates", "intends", "plans", "believes", "seeks",
"estimates" or words of similar meaning. These forward-looking
statements and their implications are based on the current
expectations of the management of XORTX only, and are subject to a
number of factors and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. Such risks, uncertainties, and other factors include,
but are not limited to, our ability to obtain additional financing;
the accuracy of our estimates regarding expenses, future revenues
and capital requirements; the success and timing of our preclinical
studies and clinical trials; the performance of third-party
manufacturers and contract research organizations; our plans to
develop and commercialize our product candidates; our plans to
advance research in other kidney disease applications; and, our
ability to obtain and maintain intellectual property protection for
our product candidates. Except as otherwise required by applicable
law and stock exchange rules, XORTX undertakes no obligation to
publicly release any revisions to these forward-looking statements
to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. More detailed
information about the risks and uncertainties affecting XORTX is
contained under the heading “Risk Factors” in XORTX’s Annual Report
on Form 20-F filed with the SEC, which is available on the SEC's
website, www.sec.gov (including any documents forming a part
thereof or incorporated by reference therein), as well as in our
reports, public disclosure documents and other filings with the
securities commissions and other regulatory bodies in Canada, which
are available on www.sedarplus.ca.
Xortx Therapeutics (TSXV:XRTX)
Historical Stock Chart
From Nov 2024 to Dec 2024
Xortx Therapeutics (TSXV:XRTX)
Historical Stock Chart
From Dec 2023 to Dec 2024